Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.13 +0.9%	$1.02	$0.81 ▼ $1.76	$26.49M	0.79	129,073 shs	33,878 shs
GBIO Generation Bio	$0.34 +5.6%	$0.38	$0.30 ▼ $3.65	$21.45M	2.59	392,243 shs	695,465 shs
IXHL Incannex Healthcare	$0.21 -1.0%	$0.23	$0.08 ▼ $3.12	$6.15M	7.47	14.66 million shs	12.52 million shs
TPST Tempest Therapeutics	$7.13 +3.3%	$6.95	$5.35 ▼ $30.03	$25.41M	-1.95	166,404 shs	76,946 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+0.89%	-10.32%	+20.21%	+19.40%	-14.39%
GBIO Generation Bio	+5.59%	-7.35%	-12.12%	-14.99%	-85.56%
IXHL Incannex Healthcare	-0.96%	-1.48%	+3.76%	-67.38%	-92.99%
TPST Tempest Therapeutics	+3.33%	-0.28%	+6.42%	-23.67%	-74.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENLV Enlivex Therapeutics	3.3196 of 5 stars	3.7	5.0	2.7	0.8	0.6
GBIO Generation Bio	3.3191 of 5 stars	3.5	3.0	1.5	3.3	1.3
IXHL Incannex Healthcare	0.8502 of 5 stars	0.0	4.0	3.3	0.8	0.0
TPST Tempest Therapeutics	1.8109 of 5 stars	3.3	2.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	784.96% Upside
GBIO Generation Bio	3.00	Buy	$7.33	2,070.27% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	320.76% Upside

Current Analyst Ratings Breakdown

Latest IXHL, ENLV, GBIO, and TPST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/10/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/10/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$16.00 ➝ $16.00
4/10/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Perform	$7.00 ➝ $9.00
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
GBIO Generation Bio	$19.89M	1.14	N/A	N/A	$1.29 per share	0.26
IXHL Incannex Healthcare	$10K	608.91	N/A	N/A	$0.18 per share	1.15
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$5.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
GBIO Generation Bio	-$131.67M	-$1.08	N/A	N/A	N/A	-292.92%	-75.84%	-30.40%	8/6/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	N/A
TPST Tempest Therapeutics	-$41.84M	-$17.98	N/A	N/A	N/A	N/A	-305.51%	-119.74%	8/6/2025 (Estimated)

Latest IXHL, ENLV, GBIO, and TPST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/13/2025	Q1 2025	TPST Tempest Therapeutics	-$3.71	-$3.16	+$0.55	-$3.16	N/A	N/A
5/7/2025	Q1 2025	GBIO Generation Bio	-$0.25	-$0.22	+$0.03	-$0.22	$1.70 million	$8.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	7.20	7.20
GBIO Generation Bio	N/A	8.43	8.43
IXHL Incannex Healthcare	N/A	2.12	2.12
TPST Tempest Therapeutics	N/A	1.70	1.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
GBIO Generation Bio	95.22%
IXHL Incannex Healthcare	0.43%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
GBIO Generation Bio	21.80%
IXHL Incannex Healthcare	15.49%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
GBIO Generation Bio	150	67.04 million	52.42 million	Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
TPST Tempest Therapeutics	20	3.68 million	3.51 million	Optionable

IXHL, ENLV, GBIO, and TPST Headlines

Recent News About These Companies

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - Nasdaq

July 2 at 9:01 AM | nasdaq.com

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China

June 30 at 8:14 AM | quiverquant.comQ

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

June 30 at 8:00 AM | globenewswire.com

TPST - Tempest Therapeutics Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

TPST Tempest Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%

June 11, 2025 | msn.com

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | quiverquant.comQ

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | globenewswire.com

Tempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic Alternatives

June 7, 2025 | marketwatch.com

Tempest Therapeutics Shares Up, Executive Team Enters Into Consulting Agreements

June 7, 2025 | marketwatch.com

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

June 6, 2025 | zacks.com

Tempest Therapeutics stock rises on EMA Orphan Drug Designation

June 5, 2025 | au.investing.com

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 5, 2025 | globenewswire.com

Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finance.yahoo.com

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 28, 2025 | globenewswire.com

Dual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

April 25, 2025 | empr.comE

Cash-strapped Bay Area biotech company lays off all but 5 employees

April 24, 2025 | msn.com

Tempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495

April 23, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, ENLV, GBIO, and TPST Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.13 +0.01 (+0.89%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$1.14 +0.02 (+1.33%)

As of 07/2/2025 04:04 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Generation Bio NASDAQ:GBIO

$0.34 +0.02 (+5.59%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$0.34 +0.00 (+1.21%)

As of 07/2/2025 07:45 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Incannex Healthcare NASDAQ:IXHL

$0.21 0.00 (-0.96%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$0.21 +0.00 (+1.98%)

As of 07/2/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Tempest Therapeutics NASDAQ:TPST

$7.13 +0.23 (+3.33%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$7.02 -0.11 (-1.47%)

As of 07/2/2025 07:30 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time